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Megakaryocytopoiesis is a complex differentiation process driven by the hormone thrombopoietin 
by which haematopoietic progenitor cells give rise to megakaryocytes, the giant bone marrow cells 
that in turn break down to form blood platelets. The Tribbles Pseudokinase 3 gene (TRIB3) encodes a 
pleiotropic protein increasingly implicated in the regulation of cellular differentiation programmes. 
Previous studies have hinted that TRIB3 could be also involved in megakaryocytopoiesis but its role in 
this process has so far not been investigated. Using cellular model systems of haematopoietic lineage 
differentiation here we demonstrate that TRIB3 is a negative modulator of megakaryocytopoiesis. We 
found that in primary cultures derived from human haematopoietic progenitor cells, thrombopoietin-
induced megakaryocytic differentiation led to a time and dose-dependent decrease in TRIB3 mRNA 
levels. In the haematopoietic cell line UT7/mpl, silencing of TRIB3 increased basal and thrombopoietin-
stimulated megakaryocyte antigen expression, as well as basal levels of ERK1/2 phosphorylation. In 
primary haematopoietic cell cultures, silencing of TRIB3 facilitated megakaryocyte differentiation. 
In contrast, over-expression of TRIB3 in these cells inhibited the differentiation process. The in-vitro 
identification of TRIB3 as a negative regulator of megakaryocytopoiesis suggests that in-vivo this gene 
could be important for the regulation of platelet production.
TRIB3, a mammalian orthologue of Drosophila Tribbles, is a member of an emerging group of genes encoding 
pseudo-kinases, which are increasingly implicated in the regulation of signal transduction and gene transcrip-
tion1, 2. Mammals express three tribbles proteins: TRIB1, TRIB2 and TRIB33. TRIB3 can bind and inhibit the 
protein kinases AKT4 and MEK15, as well as interact with E3 ubiquitin ligases such as SMURF16 and COP17, 
targeting proteins for degradation. In addition, TRIB3 can act as a transcriptional repressor by interacting with 
a number of transcription factors, including ATF48, DDIT39, C/EBPβ10 and PPARγ11. Consistent with this mul-
tiplicity of binding partners and functions, TRIB3 has been linked to the modulation of diverse biological pro-
cesses, including cellular metabolism, stress responses, cell survival, proliferation and differentiation.
Recently, in a study investigating the gene expression signature of the platelet-lowering agent anagrelide we 
found that TRIB3 is up-regulated when megakaryocytopoiesis is inhibited by this drug12. TRIB3 has also been 
listed in a microarray data set among the down-regulated genes of a thrombopoietin (TPO)-response signature13. 
While these findings raise the possibility that TRIB3 could be involved in the control of megakaryocytopoiesis, its 
function in this process has not been formally investigated.
Here we show that TRIB3 expression is down-regulated during the ex vivo differentiation of haematopoietic 
progenitor cells into the megakaryocytic lineage, that silencing of this gene enhances megakaryocyte differentia-
tion and conversely, that its over-expression inhibits this process. In addition, we provide evidence suggesting that 
the underlying mechanism of action of TRIB3 involves inhibition of the MAPK pathway. These findings identify 
TRIB3 as a potential negative modulator of megakaryocytopoiesis in haematopoietic cells.
Results
TRIB3 mRNA expression is down-regulated during megakaryocyte differentiation. To assess 
whether TRIB3 could be involved in the process of megakaryocyte differentiation we initially examined its expres-
sion in cultures of primary haematopoietic cells grown in the presence of TPO. Under these conditions there was 
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a time-dependent decrease in TRIB3 mRNA levels, with the maximal effect (~75% reduction) being observed 
after four days in culture (Fig. 1a). As shown in Fig. 1b the reduction in TRIB3 expression was maximized with 
increasing concentrations of TPO. Importantly, these changes were mirrored by a time- and dose-dependent 
increase in the expression of the megakaryocyte specific gene ITGA2B (aka, GPIIb).
Silencing of TRIB3 expression enhances megakaryocyte differentiation. To test the functional 
significance of the above described TRIB3 down-regulation we examined the effects of TRIB3 silencing in the 
haematopoietic cell line UT7/mpl, using lentiviral-mediated shRNA interference. Five TRIB3 shRNAs (desig-
nated shTRIB3.1 to shTRIB3.5) were initially surveyed in HT1080 cells. Of these, one was found to be ineffective 
(shTRIB3.1) while the other four reduced TRIB3 expression by at least 50% (data not shown). In UT7/mpl cells 
three of the four positive shRNAs also caused a marked increase in the expression of the megakaryocytic sur-
face marker CD61, under both basal and TPO-stimulated conditions, while the fourth shRNA (shTRIB3.2) only 
affected expression under basal conditions (Supplementary Table S1). Additional experiments demonstrated that 
shTRIB3.3 and shTRIB3.4 were consistently the most effective shRNAs, producing similar results. Results with 
shTRIB3.4 are shown in Fig. 2.
We next assessed whether TRIB3 silencing affected the development of megakaryocytes in liquid cultures of 
CD34+-derived human haematopoietic cells. Initial experiments with a mixture of TRIB3 shRNAs (shTRIB3.3, 
shTRIB3.4 and shTRIB3.5) showed a >50% reduction in TRIB3 mRNA expression and a marked increase in the 
final number of megakaryocytes in the cultures when compared to a control shRNA (Supplementary Fig. S1). 
Further transductions carried out with shTRIB3.4 alone resulted in a similar degree of silencing (Fig. 3a). 
Furthermore, this level of silencing resulted in a >50% increase in ITGA2B mRNA and in similar increases in the 
expression of various transcription factors known to be implicated in the execution of the megakaryocyte differ-
entiation program, namely GATA114, FOG115, FLI116 and NFE217. Accordingly, TRIB3 silencing also resulted in 
noticeable increases in the surface expression of the antigens CD61 and CD42b and in the overall percentage and 
number of differentiated megakaryocytes in the cultures (Fig. 3b,c). The potentiating action of TRIB3 silencing on 
megakaryocyte development was much more manifested at submaximal doses of TPO, both in terms of the effect 
Figure 1. TPO induces a time and dose-dependent decrease of TRIB3 mRNA levels. (a) Primary 
haematopoietic cells were grown under megakaryocyte differentiation conditions with 40 ng/mL TPO for 
the indicated lengths of time, or (b) for four days with the indicated doses of TPO. Gene expression levels 
are expressed relative to the respective transcript levels at the initiation of the culture period. Results are 
representative of three independent experiments. Error bars denote SD of technical replicates (n = 3–6). Error 
bars smaller than the size of the symbol are not shown.
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on the proportion and the absolute number of CD61+ cells in the cultures (Fig. 4). Taken together these results 
indicated that TRIB3 acts as a negative modulator of megakaryocyte differentiation.
Over-expression of TRIB3 inhibits megakaryocyte differentiation. To confirm that TRIB3 represses 
megakaryocyte differentiation, we ectopically over-expressed it in CD34+-derived human haematopoietic cells 
using a dual promoter lentiviral construct which includes eGFP as a reporter gene. We then differentiated the 
infected cells under standard megakaryocyte culture conditions. As shown in Fig. 5a, compared with an empty 
vector control, transduction with the TRIB3-engineered vector resulted in a large increase in the expression of 
Figure 2. TRIB3 silencing enhances the megakaryocytic differentiation of UT7/mpl cells. shRNA-transduced 
cells (shControl and shTRIB3.4) were grown for 7 days in the absence (basal) or presence of 100 ng/mL TPO 
(+TPO) and then analysed for TRIB3 mRNA and CD61 expression. (a) TRIB3 mRNA levels are expressed 
relative to the basal levels in shControl. Error bars denote SD of pooled Q-PCR data from two independent 
cultures (n = 6); (b–d) Flow cytometric analysis of megakaryocytic differentiation. (b) Representative density 
plots display the percentages of CD61+ cells. (c) Representative histogram plots display the median fluorescence 
intensities (MFI); the faint traces correspond to the fluorescence distribution of samples stained with an isotype-
matched control antibody. (d) Results of three independent cultures are presented as mean ± SD. *P < 0.05, 
**P < 0.01, ***P < 0.001.
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Figure 3. TRIB3 silencing enhances the megakaryocytic differentiation of primary haematopoietic cells. 
shRNA-transduced cells (shControl and shTRIB3.4) were grown for 7 days with 40 ng/mL TPO and then 
analysed for mRNA and surface marker expression. (a) mRNA levels for the indicated genes are depicted 
relative to the respective levels in shControl. Error bars denote SD of pooled Q-PCR data from two independent 
experiments (n = 6). (b,c) Flow cytometric analysis of megakaryocytic differentiation. (b) Representative 
density plots display the percentages of differentiated cells and histogram plots display the median fluorescence 
intensities of the cells encompassed within the horizontal markers. (c) Results of four independent experiments 
are presented as mean ± SD. The top panel shows the percentages of differentiated cells in the transduced 
cultures and the bottom panel shows the total number of differentiated cells, expressed as a percentage of those 
in shControl. *P < 0.05 and ***P < 0.001.
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this gene. Flow cytometric analysis of the eGFP-positive cells, showed that inclusion of the TRIB3 transgene 
resulted in a consistent decrease in the percentage of differentiated cells (Fig. 5b,c), thus confirming its inhibitory 
effect on megakaryocyte development.
Silencing of TRIB3 expression enhances the basal levels of ERK1/2 phosphorylation. To inves-
tigate the potential underlying mechanism by which TRIB3 regulates megakaryocyte differentiation we examined 
the effect of TRIB3 silencing on the phosphorylation levels of AKT and ERK1/2 in UT7/mpl cells. As shown in 
Fig. 6, compared to shControl-transduced cells, shTRIB3-transduced cells showed significantly higher basal levels 
of ERK1/2 phosphorylation. In contrast, on average, no significant differences could be detected in the basal levels 
of AKT phosphorylation or in the phosphorylation levels of each of these proteins following stimulation with 
maximal concentrations of TPO.
Discussion
The present study strongly suggests that TRIB3 may function as a negative modulator of megakaryocytopoiesis. 
This conclusion is based on the following findings: Firstly, TRIB3 expression decreased during TPO-induced 
differentiation of primary haematopoietic progenitors. Secondly, silencing of TRIB3 enhanced megakaryocyte 
differentiation, both in a megakaryocytic cell line and in normal haematopoietic progenitors. Thirdly, ectopic 
over-expression of TRIB3 attenuated the extent of this differentiation. TRIB3 has been previously implicated in 
the regulation of intracellular mechanisms that control adipocyte, muscle cell, and embryonic stem cell differen-
tiation10, 11, 18, 19. Thus, our findings add to an incipient body of evidence indicating that a major function of TRIB3 
is to act as negative regulator of terminal differentiation programmes.
A salient finding of the present study is that TPO down-regulated the expression of TRIB3 in a dose-dependent 
manner, with the decline mirroring the increase in the expression of ITGA2B. This result indicates that 
the down-regulation of TRIB3 is intimately coupled to the differentiation process. In this respect, it was also 
notable that the potentiating effect of TRIB3 silencing on the extent of differentiation was more manifested at 
sub-maximal concentrations of TPO, suggesting that the presence of TRIB3 interferes with the action of the 
hormone and hence, that its down-regulation is required for the full effect of TPO to be manifested. TPO drives 
megakaryocytopoiesis by binding to the MPL receptor and thereby choreographing changes in the activity, 
deployment and/or expression of a complex network of signalling proteins and transcription factors, which ulti-
mately coordinate a specific programme of gene expression20, 21. Precisely how TRIB3 interacts with this network 
Figure 4. TRIB3 silencing potentiates the megakaryocytopoietic activity of TPO. shRNA-transduced primary 
haematopoietic cells were grown as in Fig. 3 with either 1 or 40 ng/mL TPO and then analysed for CD61 
expression. (a) Representative histogram plots display the percentages and total number of CD61+ cells in the 
cultures; the fold change in the number of CD61+ cells relative to shControl is shown in brackets. (b) Results of 
two independent experiments are presented as mean ± SD. *P < 0.05.
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is presently unknown. However, a plausible scenario is that it normally represses a pathway that transduces a 
MPL differentiation signal, and that one of the primary actions of TPO is to down-regulate TRIB3 expression 
to de-repress this pathway. This possibility is entirely consistent with the notions that firstly, TRIB3 is known to 
inhibit the protein kinase MEK15, which is also a down-stream effector of MPL, secondly, that strong, long-lasting 
activation of the MAPK pathway is required for TPO-induced megakaryocytic lineage commitment and differ-
entiation22, 23 and thirdly, that MEK inhibitors restrict the development of megakaryocytes from human hae-
matopoietic progenitors, giving rise to a more immature phenotype24. In support of this mechanism of action we 
found that TRIB3 silencing enhanced the basal phosphorylation levels of ERK1 and ERK2, which are downstream 
MEK1 substrates. Importantly, while TPO also signals through AKT and despite the fact that in other systems 
AKT is susceptible to regulation by TRIB34, 18, in UT7/mpl cells the effect of TRIB3 silencing appeared to be 
circumscribed specifically to the MAPK pathway. Interestingly, TRIB3 silencing did not affect ERK1/2 phos-
phorylation when cells were stimulated with maximal concentrations of TPO, seemingly suggesting that strong 
MPL signalling may overcome the inhibition of MEK1 by TRIB3. Thus, more detailed phosphorylation studies 
with submaximal concentrations of TPO will be required to determine the extent to which TRIB3 affects TPO 
signalling through this pathway. Furthermore, while these findings suggest that mechanistically TRIB3 fulfils a 
specific role in the regulation of megakaryocytopoiesis, namely the inhibition of MEK1, they do not rule out the 
possibility that additionally it interacts directly with the transcription machinery that controls differentiation, as 
it was shown to be the case in cellular models of adipogenesis10, 11.
In the present work we found that silencing of TRIB3 enhanced the TPO-stimulated increase in the mRNA 
levels of GATA1, FOG1, FLI1 and NFE2. GATA1 and FOG1 are essential for complete development of the 
megakaryocytic lineage, being required from the progenitor stage throughout to the final stages of differenti-
ation14, 15 whereas FLI1 and NFE2 act at late stages, affecting primarily the early maturing megakaryocyte16, 25 
and pro-platelet formation17, respectively. Thus, while these results clearly support the conclusion that TRIB3 
suppresses megakaryocytopoiesis, they do not provide an answer as to which specific stage(s) of the process 
Figure 5. TRIB3 over-expression inhibits the megakaryocytic differentiation of primary haematopoietic 
cells. Cells transduced with control (EX-NEG) or TRIB3 (EX-TRIB3)-expressing vectors were cultured for 7 
days with 1 ng/mL TPO under megakaryocyte differentiation conditions and then analysed for mRNA and 
surface marker expression. (a) TRIB3 mRNA levels are depicted relative to the levels in EX-NEG. Error bars 
denote SD of technical replicates from one representative experiment (n = 6). (b,c) Flow cytometric analysis 
of differentiation. (b) Results of three independent experiments show the proportion of differentiated cells 
within the eGFP+ fraction; the percentage of inhibition was calculated relative to the corresponding values in 
EX-NEG and then averaged. (c) Representative density plots corresponding to Exp. 3 display the percentages of 
differentiated cells.
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it inhibits. In this context it is noteworthy that a recent study has implicated TRIB3 as a positive modulator of 
stress erythropoiesis26. Given that the differentiation of the erythroid and megakaryocytic lineages are intimately 
ligated, sharing common progenitors and overlapping signal transduction pathways, our results are also compat-
ible with the possibility that TRIB3 could be involved in the regulation of lineage fate decisions at the megakary-
ocytic/erythroid bi-potential progenitor stage. It would be therefore also interesting to analyse if Trib3 deficiency 
affects the balance between erythropoiesis and megakaryocytopoiesis under conditions of experimental-induced 
anaemia.
The dysfunction of genes known to regulate megakaryocytopoiesis has been found in some cases to cause 
platelet disorders21, 27. Whether TRIB3 also falls into this category remains to be established. In this respect, 
the present findings, together with our previous work showing that a major transcriptional effect of the 
platelet-lowering agent anagrelide was to increase TRIB3 expression12, highlight the potential role that this gene 
could play, both as a biomarker and as drug target in the development of approaches to modulate platelet counts 
in diverse pathological states.
Methods
UT7/mpl cell culture. UT7/mpl cells (clone 5.1)28 were propagated in Iscove’s modified Dulbecco’s medium 
(GIBCO Life Technologies, UK) supplemented with 10% foetal calf serum (Hyclone, Perbio Sciences, UK), 2.5 
ng/mL granulocyte-macrophage colony-stimulating factor (R&D Systems) and 0.5 mg/mL G418 as previously 
described29. To induce megakaryocytic differentiation cells were subcultured in fresh medium containing 100 ng/
mL TPO. Cultures were maintained at 37 °C in a humidified incubator under 5% CO2/ 95% air.
Figure 6. TRIB3 silencing enhances the basal levels of ERK1/2 phosphorylation in UT7/mpl cells. shRNA-
transduced cells were incubated for 30 min in the absence or presence of 100 ng/mL TPO and then analysed 
for AKT and ERK1/2 phosphorylation. Phosphoproteins were detected by immunoblotting and quantified by 
scanning densitometry. A representative immunoblot is shown in (a); quantification is shown in (b). Relative 
phosphorylation levels were calculated as the ratio of the intensity of the phosphorylated polypeptide bands 
to the intensity of the corresponding total polypeptide bands. Results are expressed relative to the level of 
phosphorylation measured in unstimulated shControl cells. Error bars denote SD of three independent cultures. 
*P < 0.05.
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Primary megakaryocyte culture. Megakaryocytes were generated ex-vivo from human umbilical cord 
blood-derived CD34+ cells in a two-step liquid culture system, as previously described12. Briefly cryopreserved 
CD34+ cells (Stem Cell Technologies, Vancouver, Canada) were first thawed and expanded for 4–5 days in 
StemspanTM medium (Stem Cell Technologies) supplemented with 2% human umbilical cord blood plasma 
and a mixture of haematopoietic growth factors consisting of TPO (Insight, UK), SCF, Flt3 ligand and IL-3 (all 
from R&D Systems, Abingdon, UK). Subsequently, to promote terminal differentiation cells were sub-cultured 
for up to ten days in fresh medium supplemented with 2% cord blood plasma and TPO only, at the indicated 
concentrations.
Lentiviral particles and cell transductions. TRC1-pLKO.1-puro plasmids carrying short hairpin 
sequences targetted against TRIB3 (shTRIB3) or a non-targeting control sequence (shControl) were obtained 
from the Mission TRC shRNA library (Sigma-Aldrich, Dorset, UK). Short hairpin sequences are listed online 
in the Supplementary Table S2. The lentiviral expression constructs EX-V1552-Lv201, which contains the 
protein-coding open reading frame of TRIB3, and the negative control EX-NEG-Lv201 were purchased from 
Genecopoeia (Rockville, MD, USA). The packaging plasmid psPAX2 and the envelop plasmid pMD2.G were 
obtained from AddGene (Cambridge, MA, USA). Lentiviral particles were produced by co-transfection of 
HEK293T cells. Pseudoviruses were harvested after 48 h and concentrated by ultrafiltration on Amicon Ultra-15 
100K filters (Millipore UK, Hertforshire, UK). Lentiviral titers were determined by transduction of HT1080 cells 
followed by drug selection and counting of puromycin-resistant colonies (for shRNAs) or by flow cytometric 
determination of eGFP+ cells (for lentiviral expression constructs).
Infection of UT7/mpl cells with lentiviral shRNAs was carried out by spinoculation at 900 g for 30 min at 21 °C 
in the presence of 4 μg/mL polybrene (Sigma-Aldrich, Dorset, UK) and at a MOI of 5, followed by overnight 
culture. Transduced cells were then selected in the presence of 1 μg/mL puromycin (Invitrogen, Paysley, UK).
Infection of CD34+ cells with lentiviral shRNAs was carried out after one day of expansion by spinoculation at 
1450 g for 90 min at 21 °C in the presence of 4 μg/mL polybrene and at a MOI of 8, followed by overnight culture. 
shRNA-transduced cells were then selected with 1 μg/mL puromycin for two days and then grown for a further 
24 h in fresh normal expansion medium prior to culture under differentiation conditions.
Infection of CD34+ cells with lentiviral expression vectors was carried out after 4 days of expansion by two 
consecutive spinoculations of 90 min each at 1450 g and 21 °C, separated by a 4 h interval, in the presence of 4 μg/
mL polybrene and at a MOI of 10, followed by overnight culture. Expression vector-transduced cells were either 
differentiated without prior selection (for flow cytometric analysis) or were selected with puromycin for the last 
two days of differentiation (for mRNA analysis).
Analysis of megakaryocytic lineage differentiation. Megakaryocytic differentiation was monitored 
by flow cytometry as previously described30 using fluorescein isothiocyanate (FITC)-, R-phycoerythrin (RPE)- or 
allophycocyanin (APC)-conjugated monoclonal antibodies against CD61 (clone Y2/51, Dako, Ely, UK) and/or 
CD42b (clone HIP1, BD Biosciences, Oxford, UK). Dead cells were excluded using 7-amino actinomycin D (1 
μg/mL, Invitrogen, Paisley, UK) or near-IR fluorescent reactive dye (1:250 dilution, Invitrogen, Paisley, UK), as 
appropriate. In experiments where the relative antigen expression was estimated using the median fluorescent 
intensity, nonspecific fluorescence of cells stained with an isotype-matched control antibody was subtracted from 
all determinations. When indicated, the number of differentiated cells was estimated by multiplying the percent-
age of antigen-positive cells by the total number of live cells in the culture.
RNA expression. Cellular RNA was extracted and then analysed by the quantitative polymerase chain 
reaction (Q-PCR) using gene-specific TaqMan probes (Applied Biosystems) as previously described31. Relative 
mRNA expression levels were calculated by the comparative cycle threshold (CT) method using β-glucuronidase 
(GUSB) or TATA-box binding protein (TBP) as internal references. Probes are listed online in the Supplementary 
Table S3.
Protein phosphorylation. AKT and ERK1/2 phosphorylation was examined by immunoblotting as previ-
ously described31. Primary antibodies are listed online in the Supplementary Table S4.
Statistical analysis. Differences between means were compared by a two tailed Student’s t-test (Graph Pad 
Prism, release 5.0). A value of p < 0.05 was considered to denote statistical significance.
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